Compare · IDXG vs SYK
IDXG vs SYK
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $126.81B.
- IDXG has been more active in the news (10 items in the past 4 weeks vs 9 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- Stryker Corporation
- Price
- -
- $330.59+0.86%
- Market cap
- -
- $126.81B
- 1M return
- -
- -1.81%
- 1Y return
- -
- -16.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 10
- 9
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest IDXG
- Interpace Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO, President & Chairman Burnell Thomas W. converted options into 1,966,763 shares and covered exercise/tax liability with 581,718 shares, increasing direct ownership by 1,954% to 1,455,927 units (SEC Form 4) to cover taxes
- SEC Form 4 filed by Director Aggarwal Vijay
- SEC Form 4 filed by Director Keegan Joseph D
- SEC Form 4 filed by Director Rocca Fortunato R.
- SEC Form 4 filed by Director Sullivan Stephen J
- CFO & COO Mccarthy Christopher converted options into 277,009 shares, increasing direct ownership by 592% to 323,800 units (SEC Form 4)
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Interpace Biosciences, Inc.
- Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation